eli lilly and company tirzepatide F.D.A. Approves New Obesity Drug That Will Compete With Wegovy FDA Approves Lilly's Zepbound™ (tirzepatide)

Compared with other PPAR agonists lanifibranor, rosiglitazone,and elafibranor, pioglitazone had a greater effect on steatosis, hepatocyte ballooning, inflammation, and fibrosis

While reduced appetite is completely normal on GLP-1s, skipping meals entirely is not recommended

This years event multi-day event in New Orleans held seminars on creatine and brain health, metabolic management, and continuous glucose monitors

Unlike direct GH administration, Tesamorelin maintains pulsatile GH release rather than producing supraphysiological spikes, making it a subject of sustained interest in metabolic and endocrine research